GeneThera, Inc. (GTHR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 6302.00 USD | -45.59% |
| 2020 | 11.58 Thousand USD | -45.24% |
| 2019 | 21.14 Thousand USD | -44.58% |
| 2018 | 38.16 Thousand USD | -81.48% |
| 2017 | 206.05 Thousand USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 146.11 Thousand USD | 847.3% |
| 2014 | 15.42 Thousand USD | -57.27% |
| 2013 | 36.09 Thousand USD | -40.42% |
| 2012 | 60.58 Thousand USD | 21.61% |
| 2011 | 49.81 Thousand USD | 259.23% |
| 2010 | 13.86 Thousand USD | -4.44% |
| 2009 | 14.51 Thousand USD | -93.46% |
| 2008 | 221.78 Thousand USD | -39.12% |
| 2007 | 364.3 Thousand USD | -7.68% |
| 2006 | 394.6 Thousand USD | -7.99% |
| 2005 | 428.86 Thousand USD | -53.06% |
| 2004 | 913.63 Thousand USD | 13.25% |
| 2003 | 806.76 Thousand USD | 148.6% |
| 2002 | 324.51 Thousand USD | 231.69% |
| 2001 | 97.83 Thousand USD | -48.51% |
| 2000 | 190 Thousand USD | -62.98% |
| 1999 | 513.22 Thousand USD | -16.2% |
| 1998 | 612.47 Thousand USD | -8.59% |
| 1997 | 670 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 Q3 | 1320.00 USD | -50.0% |
| 2022 FY | - USD | -100.0% |
| 2022 Q2 | 2640.00 USD | -33.33% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q1 | 3960.00 USD | -37.16% |
| 2021 Q1 | 10.26 Thousand USD | -11.4% |
| 2021 FY | 6302.00 USD | -45.59% |
| 2021 Q2 | 8942.00 USD | -12.86% |
| 2021 Q3 | 7622.00 USD | -14.76% |
| 2021 Q4 | 6302.00 USD | -17.32% |
| 2020 Q3 | 24.2 Thousand USD | 71.39% |
| 2020 FY | 11.58 Thousand USD | -45.24% |
| 2020 Q4 | 11.58 Thousand USD | -52.15% |
| 2020 Q2 | 14.12 Thousand USD | -2.74% |
| 2020 Q1 | 14.52 Thousand USD | -31.34% |
| 2019 Q2 | 19.33 Thousand USD | -40.0% |
| 2019 FY | 21.14 Thousand USD | -44.58% |
| 2019 Q3 | 158.5 Thousand USD | 719.93% |
| 2019 Q1 | 32.22 Thousand USD | -15.56% |
| 2019 Q4 | 21.14 Thousand USD | -86.66% |
| 2018 Q3 | 107.6 Thousand USD | -65.47% |
| 2018 Q4 | 38.16 Thousand USD | -64.54% |
| 2018 FY | 38.16 Thousand USD | -81.48% |
| 2018 Q1 | 155.31 Thousand USD | -24.62% |
| 2018 Q2 | 311.6 Thousand USD | 100.63% |
| 2017 Q4 | 206.05 Thousand USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | 206.05 Thousand USD | 0.0% |
| 2016 Q1 | 133.18 Thousand USD | -8.84% |
| 2016 FY | - USD | -100.0% |
| 2016 Q2 | 165.21 Thousand USD | 24.04% |
| 2016 Q3 | 57.19 Thousand USD | -65.38% |
| 2016 Q4 | - USD | -100.0% |
| 2015 Q3 | 396.79 Thousand USD | 30.01% |
| 2015 FY | 146.11 Thousand USD | 847.3% |
| 2015 Q2 | 305.2 Thousand USD | -4.34% |
| 2015 Q1 | 319.06 Thousand USD | 1968.6% |
| 2015 Q4 | 146.11 Thousand USD | -63.18% |
| 2014 Q4 | 15.42 Thousand USD | 34.24% |
| 2014 Q3 | 11.49 Thousand USD | -12.29% |
| 2014 FY | 15.42 Thousand USD | -57.27% |
| 2014 Q2 | 13.1 Thousand USD | -74.34% |
| 2014 Q1 | 51.05 Thousand USD | 41.45% |
| 2013 FY | 36.09 Thousand USD | -40.42% |
| 2013 Q4 | 36.09 Thousand USD | -18.37% |
| 2013 Q3 | 44.21 Thousand USD | -7.14% |
| 2013 Q2 | 47.61 Thousand USD | -7.04% |
| 2013 Q1 | 51.22 Thousand USD | -15.45% |
| 2012 Q4 | 60.58 Thousand USD | -86.21% |
| 2012 Q3 | 439.21 Thousand USD | -3.23% |
| 2012 Q2 | 453.87 Thousand USD | 798.86% |
| 2012 FY | 60.58 Thousand USD | 21.61% |
| 2012 Q1 | 50.49 Thousand USD | 1.36% |
| 2011 Q1 | 18.81 Thousand USD | 35.66% |
| 2011 Q4 | 49.81 Thousand USD | 11.65% |
| 2011 Q3 | 44.61 Thousand USD | 71.84% |
| 2011 Q2 | 25.96 Thousand USD | 38.02% |
| 2011 FY | 49.81 Thousand USD | 259.23% |
| 2010 Q4 | 13.86 Thousand USD | 23.24% |
| 2010 Q1 | 12.37 Thousand USD | -14.75% |
| 2010 FY | 13.86 Thousand USD | -4.44% |
| 2010 Q2 | 13.6 Thousand USD | 9.94% |
| 2010 Q3 | 11.25 Thousand USD | -17.28% |
| 2009 FY | 14.51 Thousand USD | -93.46% |
| 2009 Q4 | 14.51 Thousand USD | -25.11% |
| 2009 Q1 | 206 Thousand USD | -7.12% |
| 2009 Q2 | 193.21 Thousand USD | -6.21% |
| 2009 Q3 | 19.37 Thousand USD | -89.97% |
| 2008 Q3 | 243.67 Thousand USD | -6.59% |
| 2008 FY | 221.78 Thousand USD | -39.12% |
| 2008 Q4 | 221.78 Thousand USD | -8.98% |
| 2008 Q1 | 278.72 Thousand USD | -23.49% |
| 2008 Q2 | 260.86 Thousand USD | -6.41% |
| 2007 FY | 364.3 Thousand USD | -7.68% |
| 2007 Q4 | 364.3 Thousand USD | -3.81% |
| 2007 Q3 | 378.75 Thousand USD | 3.35% |
| 2007 Q2 | 366.49 Thousand USD | 0.56% |
| 2007 Q1 | 364.45 Thousand USD | -7.64% |
| 2006 FY | 394.6 Thousand USD | -7.99% |
| 2006 Q4 | 394.6 Thousand USD | -35.2% |
| 2006 Q3 | 608.92 Thousand USD | 7.68% |
| 2006 Q2 | 565.48 Thousand USD | -4.47% |
| 2006 Q1 | 591.96 Thousand USD | 38.03% |
| 2005 Q1 | 1.43 Million USD | 56.57% |
| 2005 FY | 428.86 Thousand USD | -53.06% |
| 2005 Q2 | 788.35 Thousand USD | -44.89% |
| 2005 Q4 | 428.86 Thousand USD | -31.15% |
| 2005 Q3 | 622.84 Thousand USD | -20.99% |
| 2004 FY | 913.63 Thousand USD | 13.25% |
| 2004 Q3 | 795.01 Thousand USD | 45.27% |
| 2004 Q2 | 547.28 Thousand USD | -38.5% |
| 2004 Q4 | 913.63 Thousand USD | 14.92% |
| 2004 Q1 | 889.88 Thousand USD | 10.3% |
| 2003 Q1 | 347.77 Thousand USD | 7.17% |
| 2003 Q3 | 298.15 Thousand USD | -8.77% |
| 2003 Q4 | 806.76 Thousand USD | 170.59% |
| 2003 Q2 | 326.8 Thousand USD | -6.03% |
| 2003 FY | 806.76 Thousand USD | 148.6% |
| 2002 Q3 | 586.3 Thousand USD | -1.41% |
| 2002 Q4 | 324.51 Thousand USD | -44.65% |
| 2002 FY | 324.51 Thousand USD | 231.69% |
| 2002 Q1 | 522.75 Thousand USD | 434.31% |
| 2002 Q2 | 594.7 Thousand USD | 13.76% |
| 2001 FY | 97.83 Thousand USD | -48.51% |
| 2001 Q1 | 154.11 Thousand USD | 0.0% |
| 2001 Q2 | 152.42 Thousand USD | -1.1% |
| 2001 Q3 | 147.46 Thousand USD | -3.25% |
| 2001 Q4 | 97.83 Thousand USD | -33.65% |
| 2000 Q4 | - USD | -100.0% |
| 2000 Q1 | 512.84 Thousand USD | 0.56% |
| 2000 Q2 | 471.63 Thousand USD | -8.04% |
| 2000 FY | 190 Thousand USD | -62.98% |
| 2000 Q3 | 461.77 Thousand USD | -2.09% |
| 1999 Q4 | 510 Thousand USD | -33.77% |
| 1999 Q3 | 770 Thousand USD | 0.0% |
| 1999 FY | 513.22 Thousand USD | -16.2% |
| 1998 FY | 612.47 Thousand USD | -8.59% |
| 1997 FY | 670 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | 100.0% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 100.0% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 5000.00 USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 100.0% |
| Qrons Inc. | 420.00 USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 11.94 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 107.18 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 100.0% |
| Mesoblast Limited | 667.9 Million USD | 100.0% |
| Marizyme, Inc. | 22.01 Million USD | 100.0% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 100.0% |
| Pharming Group N.V. | 462.85 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 100.0% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 100.0% |
| ContraFect Corporation | 20.67 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 100.0% |
| IMV Inc. | 31.33 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 126.22 USD | 100.0% |
| ONE Bio Corp. | 70.08 Million USD | 100.0% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 100.0% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 431.71 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.51 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 100.0% |
| Biomind Labs Inc. | 73.81 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | - USD | NaN% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 100.0% |
| GB Sciences, Inc. | 103.44 Thousand USD | 100.0% |
| Alpha Cognition Inc. | 2.45 Million USD | 100.0% |
| HST Global, Inc. | 1526.00 USD | 100.0% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 100.0% |
| Halberd Corporation | 10.13 Thousand USD | 100.0% |
| Enzolytics Inc. | 361.7 Million USD | 100.0% |
| Agentix Corp. | 261.39 Thousand USD | 100.0% |
| Resverlogix Corp. | 8.11 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 100.0% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.37 Million USD | 100.0% |
| Zenith Capital Corp. | 7410.00 USD | 100.0% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 100.0% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 100.0% |
| Kadimastem Ltd | 2.3 Million USD | 100.0% |
| Helix BioMedix, Inc. | 3.02 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 100.0% |
| BioStem Technologies, Inc. | 14.56 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 100.0% |
| LadRx Corporation | 2.3 Million USD | 100.0% |
| Cell Source, Inc. | 195.17 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 100.0% |
| NovAccess Global Inc. | 62.24 Thousand USD | 100.0% |
| Affymax, Inc. | 7.44 Million USD | 100.0% |
| Itoco Inc. | 1.4 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 100.0% |
| Mobile Lads Corp. | 52.00 USD | 100.0% |
| CytoDyn Inc. | 11.13 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 100.0% |
| SYBLEU INC | 330.46 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 100.0% |
| International Stem Cell Corporation | 5.39 Million USD | 100.0% |
| Bioxytran, Inc. | 137.63 Thousand USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 15 Million USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | - USD | NaN% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 16.57 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 864.67 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 100.0% |
| Neutra Corp. | 2851.00 USD | 100.0% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 100.0% |
| PureTech Health plc | 693.97 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 100.0% |
| IXICO plc | 15.84 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 100.0% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 100.0% |